European regulators flagged nonarteritic anterior ischemic optic neuropathy as a very rare possible side effect of semaglutide more than 15 months ago. Medscape looks at where things stand.
Recap by typeshit. Post by Medscape on X.
Dr. Nadolsky, an obesity medicine doctor, gives his take on a recent GLP-1 warning in a short clip. Tap through to see which warning he means.
2:12
A short explainer on the experimental injection people call Reta, covering why it went viral and what is known so far about its safety.
A nationwide recall now covers a GLP-1 injectable. The full story names the affected medication and explains why it was pulled.
32:25
The channel walks through FDA inspection findings of mold at suppliers and what people taking GLP-1 medications should watch for.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
The FDA classed the recall as Class II on Oct. 10. The pharmacy had received an FDA warning letter in December 2025 over sterile production problems.
Loading…